Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 4 3Phase 3 3Phase 1 3Phase NA 2Phase 2/3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 7Other 4Myeloid 3

Conditions

Myelodysplastic Syndromes 87Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Leukemia, Myeloid, Acute 66Leukemia 64Myeloproliferative Disorders 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Primary Myelofibrosis 39Leukemia, Myeloid, Chronic-Phase 39Leukemia, Myelomonocytic, Chronic 38Polycythemia Vera 32Lymphoma, Non-Hodgkin 29Lymphoma 29Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma, Mantle-Cell 25Burkitt Lymphoma 25Leukemia, Myeloid, Accelerated Phase 24Lymphoma, Large-Cell, Immunoblastic 23Lymphoma, Follicular 23Lymphoma, B-Cell, Marginal Zone 23Blast Crisis 23Thrombocythemia, Essential 20Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 18Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 17Anemia, Refractory, with Excess of Blasts 17Neoplasms, Plasma Cell 16Myelodysplastic-Myeloproliferative Diseases 16

Interventions

Imatinib Mesylate 3nilotinib 2bosutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Bronchiolitis Obliterans Syndrome × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00802841 2015-11-16

LASOR

Novartis

Phase 3 Completed
191 enrolled 13 charts
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01819389 2014-01-07

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Hospital Universitario Dr. Jose E. Gonzalez

Phase 3 Completed
10 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡